Data on the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: does it concern patients with gastric cancer?

1. Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol 2010;36:1131-1138.10.1016/j.ejso.2010.09.006Search in Google Scholar

2. Brucher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPECoverview and basics. Cancer Invest 2012;30:209-224.10.3109/07357907.2012.654871Open DOISearch in Google Scholar

3. Cotte E, Colomban O, Guitton J, Tranchand B, Bakrin N, Gilly FN, et al. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. J Clin Pharmacol 2011;51:9-18.10.1177/0091270009360980Open DOISearch in Google Scholar

4. Desantis M, Bernard JL, Casanova V, Cegarra-Escolano M, Benizri E, Rahili AM, et al. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch Surg 2015;400:37-48.10.1007/s00423-014-1253-zSearch in Google Scholar

5. Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, et al. The 30-year experience-A meta-analysis of randomised and highquality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 2017;79:1-14.10.1016/j.ejca.2017.03.030Open DOISearch in Google Scholar

6. Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2016;16:1090-1098.10.1016/S1470-2045(15)00040-6Open DOISearch in Google Scholar

7. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012;308:147-156.10.1001/jama.2012.735222782416Search in Google Scholar

8. Schipper H, Clinch JJ, Olweny CLM.: Quality of life studies: Definitions and conceptual issues; in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers; 1996:11–23.Search in Google Scholar

9. Lambert LA, Harris A. Palliative cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion : current clinical practice or misnomer? J Gastrointest Oncol 2016;7:112-121.26941989Search in Google Scholar

10. Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: A systematic review: Eur J Surg Oncol 2014;40:1605-1613.Search in Google Scholar

11. Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, et al. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991;15:530–536.10.1007/BF016756561891941Open DOISearch in Google Scholar

12. Wu HT, Peng KW, Ji ZH, Sun JH, Zhang Q. Yang XJ, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center: Eur J Surg Oncol 2016;42:1024–1034.10.1016/j.ejso.2016.04.05327179924Open DOISearch in Google Scholar

13. Shan LL, Saxena A, Shan BL, Morris DL. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A systematic review and meta-analysis: Surg Oncol 2014;23:199-210.10.1016/j.suronc.2014.10.00225466850Open DOISearch in Google Scholar

14. Wu HT, Peng KW, Ji ZH, Sun JH, Zhang Q, Yang XJ, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center. Eur J Surg Oncol 2016;42:1024-3410.1016/j.ejso.2016.04.053Search in Google Scholar

15. Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget 2016;7:52307-52316.10.18632/oncotarget.10740Search in Google Scholar

16. Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 2016;42:1123-31.10.1016/j.ejso.2016.03.016Open DOISearch in Google Scholar

17. Chia CS, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K, et al. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility? Ann Surg Oncol 2016;23:1971-1979.10.1245/s10434-015-5081-3Open DOISearch in Google Scholar

18. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-318.10.1016/S1470-2045(15)00553-7Open DOISearch in Google Scholar

19. Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009;10:121.10.1186/1745-6215-10-121280317520030854Search in Google Scholar

20. Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIOFLOT3 Trial. JAMA Oncol 2017 [unpublished data].10.1001/jamaoncol.2017.0515582428728448662Search in Google Scholar

21. Albertsmeier M, Hauer A, Niess H, Werner J, Graeb C, Angele MK. Quality of life in peritoneal carcinomatosis: A prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Dig Surg 2014;31:334-340.10.1159/00036925925471828Search in Google Scholar

22. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: Longterm survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140-3148.10.1016/j.ejca.2013.05.02723831335Search in Google Scholar

23. Jess P, Iversen LH, Nielsen MB, Hansen F, Laurberg S, Rasmussen PC. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2008;51:868-874.10.1007/s10350-008-9223-618297361Open DOISearch in Google Scholar

24. Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol 2016;23:2905-13.10.1245/s10434-016-5203-627016293Open DOISearch in Google Scholar

25. Eaton AA, Gonen M, Karanicolas P, Jarnagin WR, D'Angelica MI, DeMatteo R, et al. Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. Ann Surg Oncol 2016;23:2137-2145.10.1245/s10434-015-5077-z489125126786091Open DOISearch in Google Scholar

26. Malmström M, Klefsgard R, Ivarsson B, Roman M, Johansson J. Quality of life measurements as an indicator for timing of support after oesophagectomy for cancer: a prospective study. BMC Health Serv Res 2015;15:96.10.1186/s12913-015-0747-x440999025890232Search in Google Scholar